Comment published about antisense delivery

We have recently published in Genética Médica journal an commentary (in Spanish) titled “Cómo mejorar la distribución de los medicamentos antisentido para acelerar su tránsito a la clínica” discussing antisense oligonucleotides mechanism of action; going through the drugs based on this technology that have been already approved by the Food and Drug Administration (FDA) and explaining the main issues that difficult their transition to the clinic. We also review some possible strategies to improve antisense delivery and the role of networks such as COST Actions in solving this hurdle.  

 

You may find the article here: https://revistageneticamedica.com/2018/10/15/gmg-o007-medicamentos-antisentido/